- 1
- 2
Achelios Therapeutics
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.
Dr. Crist Frangakis
President & ceoCrossject USA Inc
Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your Licensing-in strategy and how we might work together.
Don Zinn
VP US BusinessEpicentRx
EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.
Henry Han
BD HeadGenervon Biopharmaceuticals
There is a high unmet need for central nervous system (CNS) diseases in the growing aging population. Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases related to aging. Genervon is bringing GM6, a new clinical-stage drug asset, to regulatory approval and commercialization in China for CNS diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. Most clinical trials for drugs developed through the traditional single-target drug approach have failed to treat the complex neurological disorders that involve multiple interrelated pathways.
GM6 is an innovative first-in-class regulator peptide drug in clinical stage. Genervon Biopharmaceuticals discovered an endogenous embryonic-stage regulator, Motoneuronotrophic Factor (MNTF), and developed from it the pleiotropic drug GM6. GM6 is neither an antibody nor a single-target agonist or antagonist. It is a multi-target regulator which simultaneously acts upon multiple extracellular receptors to modulate a series of signaling pathways mediating inflammation and pro-survival responses in both CNS and immune system. Genervon has validated GM6’s target engagement of multiple targets and druggability. GM6 has been de-risked for toxicity in animal studies and safety in three clinical trials. IND documents filed with the FDA can be used to support regulatory filing in China for clinical trials. Genervon is interested to partner through licensing or merger and acquisition. A complete CMC package is ready for technology transfer.
Dorothy Ko
Chief Operating OfficerGenova Inc
Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ,the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn
Mr. Kenneth Xu
Vice President & Corporate SecretaryiX Biopharma Ltd
Yuhuan Wang
Senior BD ManagerKintor Pharmaceuticals
Mr. Mark Chen
BD DirectorLuye pharma
Dr Fang Zhang
Senior Business Development ManagerMs. Jieyun Hao
HR managerMr. Jibo Wang
RA specialistRancho Santa Fe Bio,Inc.
We licensed the drug from the Mayo Clinic and the drug has been part of the NIH's NCAT's Program in which they put in $5 million for our Phase I and Phase II clinical trials and Sanofi put in another $1 million for manufacturing.
We are raising a Series A round now and we welcome interest from Chinese investors and partners.
You can reach me at 858-205-5091.
Thanks.
----Randy Berholtz